In NSCLC, the combination of olaparib and durvalumab showed a poorer median PFS in patients with mutations in HRR genes, compared to those without (3.9 months [95% CI, 1.8–7.5] vs 7.4 months [95% CI, 5.5–9.3]), while PD-L1 expression greater than 50% was associated with a better PFS (10.1 months [95% CI, 3.7–not reached] vs 5.7 months [95% CI, 2.8–8.8] in patients with PD-L1-null tumours). The gene discussed is CD274; the disease is neoplasm.